Euronext-listed Dassault Syst\u00e8mes, a France-based multinational software corporation, has agreed to acquire US-based ArisGlobal, an AI-native enterprise compliance platform for the Life Sciences industry, for approximately US$1.8bn in cash at closing and up to US$200m in additional consideration linked to multi-year AI-related revenue milestones.<\/p>\n
Founded in 1989, ArisGlobal\u2019s AI-native enterprise compliance platform serves over 200 customers, including half of the Top 50 global biopharma companies as well as biotech, medtech, CROs and global health authorities. Its regulated core platform is deeply embedded within mission-critical operations and processes more than 12 million patient safety reports annually. ArisGlobal has over 1,300 employees globally and generated revenues of \u20ac150m (US$171m) in 2025. Revenues for 2026 are expected at US$175m.<\/p>\n
Its NavaX AI platform operationalises clinical-grade AI at production scale within highly regulated environments. It delivers more than 30% productivity gains, helping customers automate complex processes, improve data quality, strengthen compliance and generate decision-grade intelligence across the product lifecycle.<\/p>\n
\u201c[The transaction] marks a major milestone in our ambition to transform the Life Sciences industry by connecting molecule, patient and real-world outcomes,\u201d said Pascal Daloz<\/a>, Dassault Syst\u00e8mes\u2019 CEO and chairman.<\/p>\n Life Sciences is entering a new era of innovation \u2013 driven by artificial intelligence and the shift to precision medicine \u2013 while facing increasing operational complexity and regulatory scrutiny.<\/p>\n \u201cOur vision to virtualise the industry has never been more relevant,\u201d said Daloz. \u201cBy bringing together real-world evidence with our unique modeling and simulation expertise, this unified data and intelligence platform radically improves our ability to address persistent drug development challenges, allowing our customers to deliver safer, innovative therapies at a faster pace.\u201d<\/p>\n The transaction represents a full exit for Nordic Capital and marks the successful culmination of a partnership that has transformed ArisGlobal into a scaled, cloud-native and AI-enabled platform serving more than 200 life sciences companies, CROs and government health authorities worldwide. The Sweden-based PE firm first invested in ArisGlobal in 2019, partnering with the founding family and management team to pursue an ambitious development strategy. In 2021, Nordic Capital made a further investment in the company.\u00a0Throughout the ownership period, Nordic Capital worked closely with management to accelerate the SaaS transition, professionalise the go-to-market organisation, broaden the product offering and strengthen the leadership team.<\/p>\n \u201cNordic Capital invested in ArisGlobal because the business had strong fundamentals, a loyal blue-chip client base and significant potential to modernise its technology and scale its commercial reach,\u201d said Daniel Berglund<\/a>, partner and head of Healthcare, Nordic Capital Advisors. \u201c[We have] supported the company\u2019s transformation into a leading cloud-native platform for the life sciences industry with differentiated AI-enabled capabilities and a strengthened market position. . . and look forward to seeing the company continue to grow under Dassault Syst\u00e8mes ownership.\u201d<\/p>\n Alongside its technology transformation, ArisGlobal strengthened its management team and commercial organisation, while two strategic acquisitions in 2023 (Amplexor Life Science and Sporify) broadened the company\u2019s platform capabilities. As rising regulatory complexity and increasing volumes of adverse event reporting continue to drive demand for advanced life sciences software, ArisGlobal is well positioned for future growth through solutions that automate compliance workflows, reduce manual processing and enable organisations to manage regulatory risk more effectively.<\/p>\n \u201cThe life sciences industry is at an inflection point as regulatory complexity is increasing, data volumes are growing and our clients need software that can keep pace. The partnership with Nordic Capital gave us the resources and the runway to build exactly that,\u201d said Aman Wasan<\/a>, CEO, ArisGlobal. \u201cThe future of Life Sciences will not be built on better software \u2013 it will be built on connected intelligence. By joining Dassault Syst\u00e8mes, we are taking a major step forward in our vision to offer Life Sciences customers an integrated and comprehensive AI-first intelligence platform unifying fragmented datasets and ultimately delivering better health outcomes for patients at an accelerated pace.\u201d<\/p>\n Evercore and Jefferies acted as financial advisors to ArisGlobal and Kirkland & Ellis acted as legal advisor to ArisGlobal.<\/p>\n Nordic Capital is a member of the European Healthcare Investor Association<\/a> (EHIA). \u00a0Investors in Healthcare is the official journal of the EHIA.<\/p>\n